Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH900062 single and multiple rising dose study in healthy adults
NL-OMON32905Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of SCH900062 in confusion, Alzheimer's disease (AD) and schizophrenia, sponsored by Merck & Co. Primary endpoint: Safety and tolerability. Started Dec 2009; status: active, not recruiting.
02
Drugs
SCH900062
03
Conditions
confusionAlzheimer's disease (AD)schizophrenia
Beyond the preview
Go deeper on NL-OMON32905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32905.